Who are Tecemotide (L-BLP25)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): D-cure, CPA, PCRA (Intermittent injection), VEC, PANVAC™-VF, TAK-019.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tecemotide-l-blp25.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Tecemotide (L-BLP25) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tecemotide (L-BLP25) (Tecemotide (L-BLP25)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cancer vaccine. Area: Oncology.

phase 3 Cancer vaccine MUC1 (mucin 1) tumor-associated antigen Oncology Biologic Live · refreshed every 30 min

Target snapshot

Tecemotide (L-BLP25) (Tecemotide (L-BLP25)) — Merck KGaA, Darmstadt, Germany. Tecemotide is a cancer vaccine that stimulates the immune system to recognize and attack cancer cells expressing MUC1 antigen.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Tecemotide (L-BLP25) TARGET	Tecemotide (L-BLP25)	Merck KGaA, Darmstadt, Germany	phase 3	Cancer vaccine	MUC1 (mucin 1) tumor-associated antigen
D-cure	D-cure	KU Leuven	marketed	Therapeutic cancer vaccine
CPA	CPA	ImmunoVaccine Technologies, Inc. (IMV Inc.)	marketed	Therapeutic cancer vaccine
PCRA (Intermittent injection)	PCRA (Intermittent injection)	Örebro University, Sweden	marketed	Cancer vaccine / Autologous cell therapy
VEC	VEC	Centre Leon Berard	marketed	Therapeutic cancer vaccine
PANVAC™-VF	PANVAC™-VF	Therion Biologics Corporation	phase 3	Therapeutic cancer vaccine	ras and CEA (carcinoembryonic antigen)
TAK-019	TAK-019	Takeda	phase 3	Therapeutic cancer vaccine	Patient-specific tumor neoantigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cancer vaccine class)

Advaxis, Inc. · 3 drugs in this class
Agenus Inc. · 1 drug in this class
European Organisation for Research and Treatment of Cancer - EORTC · 1 drug in this class
Fundacion Clinic per a la Recerca Biomédica · 1 drug in this class
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · 1 drug in this class
Merck KGaA, Darmstadt, Germany · 1 drug in this class
National Cancer Institute (NCI) · 1 drug in this class
TD Vaccines A/S · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tecemotide (L-BLP25) — Competitive Intelligence Brief. https://druglandscape.com/ci/tecemotide-l-blp25. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab